[HTML][HTML] Autophagy-lysosomal pathway as potential therapeutic target in Parkinson's disease
SR Bonam, C Tranchant, S Muller - Cells, 2021 - mdpi.com
Cellular quality control systems have gained much attention in recent decades. Among
these, autophagy is a natural self-preservation mechanism that continuously eliminates toxic …
these, autophagy is a natural self-preservation mechanism that continuously eliminates toxic …
[HTML][HTML] Chemical mitophagy modulators: drug development strategies and novel regulatory mechanisms
Y Dong, XX Zhuang, YT Wang, J Tan, D Feng… - Pharmacological …, 2023 - Elsevier
Maintaining mitochondrial homeostasis is a potential therapeutic strategy for various
diseases, including neurodegenerative diseases, cardiovascular diseases, metabolic …
diseases, including neurodegenerative diseases, cardiovascular diseases, metabolic …
BNIP3L/NIX regulates both mitophagy and pexophagy
LP Wilhelm, J Zapata‐Muñoz, B Villarejo‐Zori… - The EMBO …, 2022 - embopress.org
Mitochondria and peroxisomes are closely related metabolic organelles, both in terms of
origin and in terms of function. Mitochondria and peroxisomes can also be turned over by …
origin and in terms of function. Mitochondria and peroxisomes can also be turned over by …
[HTML][HTML] Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model
TSZ Fang, Y Sun, AC Pearce, S Eleuteri… - Nature …, 2023 - nature.com
Mutations in SNCA, the gene encoding α-synuclein (αSyn), cause familial Parkinson's
disease (PD) and aberrant αSyn is a key pathological hallmark of idiopathic PD. This α …
disease (PD) and aberrant αSyn is a key pathological hallmark of idiopathic PD. This α …
[HTML][HTML] USP30: structure, emerging physiological role, and target inhibition
F Wang, Y Gao, L Zhou, J Chen, Z Xie, Z Ye… - Frontiers in …, 2022 - frontiersin.org
Ubiquitin-specific protease 30 (USP30) is a deubiquitinating enzyme (DUB) belonging to the
USP subfamily, which was found localized in the mitochondrial outer membrane and …
USP subfamily, which was found localized in the mitochondrial outer membrane and …
Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches
E Tsefou, AS Walker, EH Clark, AR Hicks… - Biochemical …, 2021 - portlandpress.com
Mitochondrial dysfunction is implicated in Parkinson disease (PD). Mutations in Parkin, an
E3 ubiquitin ligase, can cause juvenile-onset Parkinsonism, probably through impairment of …
E3 ubiquitin ligase, can cause juvenile-onset Parkinsonism, probably through impairment of …
[HTML][HTML] Deubiquitinases in neurodegeneration
AI Bello, R Goswami, SL Brown, K Costanzo, T Shores… - Cells, 2022 - mdpi.com
Ubiquitination refers to the conjugation of the ubiquitin protein (a small protein highly
conserved among eukaryotes) to itself or to other proteins through differential use of …
conserved among eukaryotes) to itself or to other proteins through differential use of …
[HTML][HTML] Role of Deubiquitinases in Parkinson's Disease—Therapeutic Perspectives
PYØ Nielsen, J Okarmus, M Meyer - Cells, 2023 - mdpi.com
Parkinson's disease (PD) is a neurodegenerative disorder that has been associated with
mitochondrial dysfunction, oxidative stress, and defects in mitophagy as well as α-synuclein …
mitochondrial dysfunction, oxidative stress, and defects in mitophagy as well as α-synuclein …
[PDF][PDF] A PINK1 input threshold arises from positive feedback in the PINK1/Parkin mitophagy decision circuit
CS Waters, SB Angenent, SJ Altschuler, LF Wu - Cell reports, 2023 - cell.com
Mechanisms that prevent accidental activation of the PINK1/Parkin mitophagy circuit on
healthy mitochondria are poorly understood. On the surface of damaged mitochondria …
healthy mitochondria are poorly understood. On the surface of damaged mitochondria …
The ubiquitin proteasome system as a therapeutic area in Parkinson's disease
K Suresh, M Mattern, MS Goldberg, TR Butt - NeuroMolecular Medicine, 2023 - Springer
Parkinson's disease (PD) is the most common neurodegenerative movement disorder.
There are no available therapeutics that slow or halt the progressive loss of dopamine …
There are no available therapeutics that slow or halt the progressive loss of dopamine …